JP2025501682A5 - - Google Patents

Info

Publication number
JP2025501682A5
JP2025501682A5 JP2024532799A JP2024532799A JP2025501682A5 JP 2025501682 A5 JP2025501682 A5 JP 2025501682A5 JP 2024532799 A JP2024532799 A JP 2024532799A JP 2024532799 A JP2024532799 A JP 2024532799A JP 2025501682 A5 JP2025501682 A5 JP 2025501682A5
Authority
JP
Japan
Prior art keywords
gapmer oligonucleotide
inventions
oligonucleotide according
spacer
gapmer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024532799A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025501682A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/051663 external-priority patent/WO2023102188A1/en
Publication of JP2025501682A publication Critical patent/JP2025501682A/ja
Publication of JP2025501682A5 publication Critical patent/JP2025501682A5/ja
Pending legal-status Critical Current

Links

JP2024532799A 2021-12-03 2022-12-02 改変された骨格化学を有するギャップマーアンチセンスオリゴヌクレオチド Pending JP2025501682A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US202163285705P 2021-12-03 2021-12-03
US202163285665P 2021-12-03 2021-12-03
US202163285696P 2021-12-03 2021-12-03
US202163285692P 2021-12-03 2021-12-03
US202163285888P 2021-12-03 2021-12-03
US63/285,705 2021-12-03
US63/285,888 2021-12-03
US63/285,665 2021-12-03
US63/285,692 2021-12-03
US63/285,696 2021-12-03
PCT/US2022/051663 WO2023102188A1 (en) 2021-12-03 2022-12-02 Gapmer antisense oligonucleotides with modified backbone chemistries

Publications (2)

Publication Number Publication Date
JP2025501682A JP2025501682A (ja) 2025-01-23
JP2025501682A5 true JP2025501682A5 (OSRAM) 2025-12-10

Family

ID=86613042

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024532799A Pending JP2025501682A (ja) 2021-12-03 2022-12-02 改変された骨格化学を有するギャップマーアンチセンスオリゴヌクレオチド

Country Status (5)

Country Link
EP (1) EP4441224A4 (OSRAM)
JP (1) JP2025501682A (OSRAM)
CN (1) CN119452086A (OSRAM)
CA (1) CA3241316A1 (OSRAM)
WO (1) WO2023102188A1 (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240126870A (ko) 2021-12-22 2024-08-21 캠프4 테라퓨틱스 코포레이션 조절 rna들을 표적으로 하는 안티센스 올리고뉴클레오티드를 사용한 유전자 전사의 조절

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU95114435A (ru) 1992-12-14 1997-05-20 Ханивелл Инк. (Us) Система с бесщеточным двигателем постоянного тока
WO1995006731A2 (en) * 1993-09-02 1995-03-09 Ribozyme Pharmaceuticals, Inc. Non-nucleotide containing enzymatic nucleic acid
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
CA2303299C (en) 1997-09-12 2016-02-23 Exiqon A/S Oligonucleotide analogues
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
NZ514348A (en) 1999-05-04 2004-05-28 Exiqon As L-ribo-LNA analogues
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
WO2004041889A2 (en) 2002-11-05 2004-05-21 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
WO2004043979A2 (en) 2002-11-05 2004-05-27 Isis Pharmaceuticals, Inc. Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
EP1661905B9 (en) 2003-08-28 2012-12-19 IMANISHI, Takeshi Novel artificial nucleic acids of n-o bond crosslinkage type
JP5379347B2 (ja) 2003-09-18 2013-12-25 アイシス ファーマシューティカルズ， インコーポレーテッド ４’−チオヌクレオシドおよびオリゴマー化合物
EP1869076A2 (en) * 2005-03-10 2007-12-26 Genentech, Inc. Methods and compositions for modulating vascular integrity
ES2351674T3 (es) 2006-01-27 2011-02-09 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos modificados en la posición 6.
CN101460178B (zh) * 2006-04-07 2016-12-07 艾德拉药物股份有限公司 用于tlr7和tlr8的稳定化的免疫调节性rna(simra)化合物
EP2505648A1 (en) * 2006-05-05 2012-10-03 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of PTP1B
CA2651453C (en) 2006-05-11 2014-10-14 Isis Pharmaceuticals, Inc. 5'-modified bicyclic nucleic acid analogs
WO2008101157A1 (en) 2007-02-15 2008-08-21 Isis Pharmaceuticals, Inc. 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom
WO2008132234A2 (en) * 2007-05-01 2008-11-06 Santaris Pharma A/S Rna antagonist compounds for the modulation of beta-catenin
EP2170917B1 (en) 2007-05-30 2012-06-27 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2173760B2 (en) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
EP2176280B2 (en) 2007-07-05 2015-06-24 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
KR101110013B1 (ko) * 2007-10-05 2012-02-29 (주)바이오니아 서열 내에 어베이직 부분을 포함하는 ｐｃｒ 증폭용프라이머
RU2593939C2 (ru) 2008-11-13 2016-08-10 Ногра Фарма Лимитед Антисмысловые композиции и способы их получения и применения
JP6129844B2 (ja) * 2011-09-14 2017-05-17 ラナ セラピューティクス インコーポレイテッド 多量体オリゴヌクレオチド化合物
CA2884608C (en) * 2012-09-14 2025-05-20 Translate Bio Ma, Inc. MULTIMERIC OLIGONUCLEOTIDE COMPOUNDS
SG10201804331TA (en) * 2012-11-15 2018-07-30 Roche Innovation Ct Copenhagen As Oligonucleotide conjugates
WO2014130945A1 (en) * 2013-02-25 2014-08-28 Integrated Dna Technologies, Inc. Modifications for antisense compounds
CA2921162A1 (en) 2013-05-01 2014-11-06 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
WO2016024205A1 (en) * 2014-08-15 2016-02-18 Pfizer Inc. Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene
EP4678748A2 (en) * 2015-12-21 2026-01-14 Novartis AG Compositions and methods for decreasing tau expression
CA3106986A1 (en) * 2018-07-25 2020-01-30 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing atxn2 expression
KR20220035137A (ko) * 2019-06-21 2022-03-21 큐랄리스 코포레이션 Ppm1a 억제제 및 그의 사용 방법

Similar Documents

Publication Publication Date Title
JP2024543214A5 (OSRAM)
JP2022536085A5 (OSRAM)
CN111373043B (zh) 用于降低snca表达的化合物和方法
US20250051766A1 (en) Treatment of neurological diseases using modulators of unc13a gene transcripts
JP6253590B2 (ja) Ｈｍｇｂ１断片を利用した脊髄の損傷に対する新規治療法
US20230125137A1 (en) Unc13a antisense oligonucleotides
TWI870557B (zh) 用於調節ｓｍｎ２之化合物及方法
EP1737438B1 (en) Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome
WO2023102242A2 (en) Splice switcher antisense oligonucleotides with modified backbone chemistries
JP2023507926A5 (OSRAM)
CN106102733B (zh) 一种用于在治疗椎间盘相关性疼痛中使用的组合物
TWI818286B (zh) 包括表現腫瘤壞死因子可誘導基因６的間葉幹細胞之組成物及藥物組成物
JP2023528435A5 (OSRAM)
CN119452086A (zh) 具有修饰的主链化学的gapmer反义寡核苷酸
JP2025514346A (ja) Ｓｙｆ２アンチセンスオリゴヌクレオチド
JP2026504486A (ja) Ｐｉｋｆｙｖｅアンチセンスオリゴヌクレオチド
CA2610413A1 (en) Uses of oligonucleotides stimulatory of the mesenchymal stem cell proliferation
JP2008184396A (ja) 神経損傷に起因する身体機能障害の予防及び治療のための医薬
Bertolín-Guillén et al. Serotonin syndrome due to association of venlafaxine, maprotiline and reboxetine
Rabie et al. Temporomandibular joint pathology and its indication in clinical orthodontics
JP7034314B2 (ja) うつ病を予防または治療するための安息香酸またはその塩および誘導体
Calvani et al. Personal orbicularis mouth muscle suspension technique for lip augmentation
US20240342175A1 (en) Compositions and Methods for Treating Spinal Cord Injury and Synaptic Dysfunction
CN120882871A (zh) 用于治疗神经系统病症的方法
TW202540422A (zh) 用於治療與ｕｂｅ３ａ過表現相關之疾患之組合物及方法